PLATELET HYPERACTIVATION IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA IS NOT ASSOCIATED WITH VASCULAR ENDOTHELIAL-CELL DAMAGE AS JUDGED BY THE LEVEL OF PLASMA THROMBOMODULIN, PROTEIN-S, PAI-1, T-PA AND VWF
S. Bellucci et al., PLATELET HYPERACTIVATION IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA IS NOT ASSOCIATED WITH VASCULAR ENDOTHELIAL-CELL DAMAGE AS JUDGED BY THE LEVEL OF PLASMA THROMBOMODULIN, PROTEIN-S, PAI-1, T-PA AND VWF, Thrombosis and haemostasis, 70(5), 1993, pp. 736-742
The occurrence of thrombotic events remains an important clinical prob
lem in Essential Thrombocythemias (ET). Thus, hemostatic, fibrinolytic
and vascular status was investigated in 16 patients (5 males and 11 f
emales) with ET. Among them five presented thromboses in their past hi
story. Platelet hyperactivation, as evidenced by a mean three-fold inc
rease in plasma betathromboglobulin (betaTG), was observed in 13 among
16 patients; surprisingly this activation was present even when the p
latelet count was normal (in two patients) or subnormal, below 600 x 1
0(9)/l (in 11 patients). The mean value was 104 +/- 57 IU/ml significa
ntly different from that of normal controls (35 +/- 16.5 IU/ml) (p < 0
.001). An artefactual in vitro platelet activation was ruled out by th
e concomitant measurement of platelet factor 4 (PF4). D-dimers fibrin
degradation products (D-Di FDP) were normal in all patients. Vascular
endothelial cell function parameters were not markedly modified. The m
ean value of plasma thrombomodulin (TM) was found slightly but not sig
nificantly increased (60.1 +/- 4.9 ng/ml versus 49.1 +/- 10.0 ng/ml in
controls). The values of plasma TM correlated neither with that of th
e platelet count nor with that of plasma betaTG or plasma PF4. The mea
n values of plasma protein S, von Willebrand factor (vWF), plasminogen
activator inhibitor type 1 (PAI-1), tissue plasminogen activator (tPA
) were normal and were not correlated neither with that of plasma TM n
or with that of plasma betaTG. In spite of a significant increase in v
WF in two patients who presented peripheral thromboses, the markers of
vascular endothelial cell function were not significantly different i
n patients having presented or not thromboses. Thus, in ET, these data
showed the presence of platelet hyperactivation, even in patients in
remission; it was not associated with vascular endothelial cell damage
which might account for a greater risk of thrombosis.